The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

GSK's RSV vaccine works by using a small piece of the virus: a protein that sticks out on its surface called the fusion, or F, protein, which helps the virus glom onto and infect cells in the body ...

GSK's RSV vaccine is approved in the US for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk.

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also ...

GSK's RSV vaccine is approved in the U.S. to prevent lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, as well as those aged 50-59 years at increased risk for LRTD ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.

GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due ...

GSK said two of its vaccines obtained a positive recommendation from a U.S. body, aiming at tackling meningitis and the respiratory syncytial virus. The pharmaceutical company said Thursday that ...

Pfizer, GSK settle patent lawsuit over RSV vaccines Apr. 04, 2025 7:50 AM ET Pfizer Inc. (PFE) Stock, GSK Stock AGEN By: Dulan Lokuwithana, SA News Editor 6 Comments ...